Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > BTD and pre-BTD overview
View:
Post by N0taP00p on Oct 09, 2023 3:32pm

BTD and pre-BTD overview

While we wait, a useful link with additional YouTube links to detailed examples for oncology.  From 2015, but should still give an idea of how BTD requests progress and what is needed.
https://www.brookings.edu/events/breakthrough-therapy-designation-exploring-the-qualifying-criteria/
Comment by N0taP00p on Oct 09, 2023 3:58pm
According to the details from 8 years ago, pre-BTD seems to be a 15 minute phone call with an expert FDA panel with no more than 2 pages of info. If you look at the bullet points, TLT should have already covered all of those under the fast track umbrella.  Maybe they still want companies to follow this process to weed out incompleteness, or validate that the prior assertions made are still ...more  
Comment by FGPstock on Oct 10, 2023 10:29am
  yea, seems like they screwed up again.... in their nov 2022 nr saying they were applying for btd in q4 2022, there was no mention of any pre-btd process and we all started the 60 day clock. Many said Dr Vera left Tlt because she already delivered on the btd and accomplished her task, but it seems she may have been frustrated at tlt
Comment by DJDawg on Oct 10, 2023 11:06am
I'm not sure what you mean be screwup. The BTD process always has had a pre-BTD check in. It is on the FDA website as an opportunity to review the details and clarify if ready for BTD. It is a good thing as the person doing the pre-BTD look over knows more about what would be accepted or not accepted and can tell you what to do to optimize success of application.
Comment by Lesalpes29 on Oct 10, 2023 11:43am
FGP here trying to mislead people again? Shame on you FGP... 
Comment by FGPstock on Oct 10, 2023 1:42pm
I am misleading or tlt is? See below, from 11 months ago. 2) Break Through Designation Update. In 2021, Theralase® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 assessments for 25 patients, expected in ...more  
Comment by DJDawg on Oct 10, 2023 2:16pm
I see what you mean. Management incompetence more than outright misleading is the usual explanation with TLT. Tlt's motto should be "For the science, invest, despite all the rest"
Comment by TriumphSpitSix on Oct 10, 2023 2:57pm
So the issue with that quote is that it is chock full of ambiguity allowing multiple interpretations. Whether it was intended to mislead I don't know, but they certainly avoided being pinned down on any particular milestone to a stated timeline. Of course, you all likely know "ambiguity" is a standard corporate communications strategy allowing them to make seemingly definite ...more  
Comment by O12009 on Oct 10, 2023 3:16pm
That maybe when it was discussed with FDA and the first 12 under treated were removed from the data so we had to what until more were treated and reached important milestones?
Comment by Oilminerdeluxe on Oct 10, 2023 3:46pm
My thought too.
Comment by 99942Apophis on Oct 10, 2023 4:00pm
FPGstock wrote 2) Break Through Designation Update. In 2021, Theralase® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 assessments for 25 patients, expected in 4Q2022, subject to the CSS’s ...more  
Comment by TriumphSpitSix on Oct 10, 2023 4:58pm
2) Break Through Designation Update. In 2021, Theralase® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 assessments for 25 patients, expected in 4Q2022, subject to the CSS’s availability to complete ...more  
Comment by FGPstock on Oct 10, 2023 9:25pm
  triumph, if the ceo of a company makes a statement that they expect to apply for btd within 30 day period, ppl should b able to rely on that. Then the new ceo rdw squared told us at the agm he expected to file within "days". I understand to some I am not allowed an opinion unless I am a blind cheerleader, but I think statements like these are reckless and irresponsible. Just an ...more  
Comment by Oilminerdeluxe on Oct 11, 2023 1:39am
He did not say he expected it to be filed. He said it "could" be filed, if memory recalls.. Those attending might know more of this. Obviously things have taken time for one reason or another. Roger is clumsy at times, but I think he follows whatever recommendations are given to him. I would love to hear about BTD being filed, so I hope it happens asap.
Comment by Lesalpes29 on Oct 11, 2023 7:57am
The past is the past no? Noise noise noise! I Look only to the next step, it will 'probably' be BTD followed by AA not too far after. GLTAL 
Comment by Tcwtaeugene2 on Oct 11, 2023 4:44pm
   Next step could be anything and there are other means to destroy cancer. This is one but other protocol seams to overcom that one in the future like ARM messenger that big pharma are working whit. So, for me it is just a possibility of succes(this mean dont put all your money on it). Dear prudence is need here. E So sf disapear? Robot?
Comment by Infinity on Oct 10, 2023 2:54pm
I think the PreBTD Is some form of explanation that ir is still Work in progress.  I get it that FDA is not an easy organisation to work without a Lobbyist who is well versed in this area.  TLT Keeps moving their target dates at the expense of credibility.  Hopefully we are very close to BTD and AA.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250